TOP TEN perturbations for 1553432_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553432_s_at
Selected probe(set): 1553432_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553432_s_at (1553432_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

galectin-1 study 1 / vehicle (DTT/polym. B) treated monocyte sample

Relative Expression (log2-ratio):-2.2899628
Number of Samples:3 / 3
Experimental galectin-1 study 1
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, galectin-1 (20 μM) in the presence of 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.
Control vehicle (DTT/polym. B) treated monocyte sample
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.

cutaneous sarcoidosis study 1 (lesional) / normal skin tissue

Relative Expression (log2-ratio):1.9662123
Number of Samples:13 / 5
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control normal skin tissue
Skin biopsy samples from healthy control subjects.

PMA study 2 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):1.7273045
Number of Samples:3 / 2
Experimental PMA study 2
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

cutaneous sarcoidosis study 1 (lesional) / cutaneous sarcoidosis study 1 (non-lesional)

Relative Expression (log2-ratio):1.7196474
Number of Samples:13 / 9
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control cutaneous sarcoidosis study 1 (non-lesional)
Non-lesional skin biopsies from patients with acute cutaneous sarcoidosis.

PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):1.639843
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

human AB serum study 1 (intermediate) / IL-4; GM-CSF study 1 (intermediate)

Relative Expression (log2-ratio):1.6036701
Number of Samples:3 / 7
Experimental human AB serum study 1 (intermediate)
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.

leprosy study 1 (LL) / leprosy study 1 (BTL)

Relative Expression (log2-ratio):1.571331
Number of Samples:6 / 10
Experimental leprosy study 1 (LL)
Lesional skin biopsy samples from patients with lepromatous leprosy (LL).
Control leprosy study 1 (BTL)
Lesional skin biopsy samples from patients with borderline tuberculoid leprosy (BTL)

male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-1.4915514
Number of Samples:2 / 8
Experimental male infertility study 1 (juvenile; Ad-)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

leprosy study 1 (RRL) / leprosy study 1 (LL)

Relative Expression (log2-ratio):-1.444624
Number of Samples:6 / 6
Experimental leprosy study 1 (RRL)
Lesional skin biopsy samples from patients with reversal reaction leprosy (RRL)
Control leprosy study 1 (LL)
Lesional skin biopsy samples from patients with lepromatous leprosy (LL).

PMA study 2 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):1.4357243
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

Organism: Homo sapiens
Gene: 1553432_s_at
Selected probe(set): 1553432_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553432_s_at (1553432_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

galectin-1 study 1 / vehicle (DTT/polym. B) treated monocyte sample

Relative Expression (log2-ratio):-2.2899628
Number of Samples:3 / 3
Experimental galectin-1 study 1
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, galectin-1 (20 μM) in the presence of 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.
Control vehicle (DTT/polym. B) treated monocyte sample
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.

cutaneous sarcoidosis study 1 (lesional) / normal skin tissue

Relative Expression (log2-ratio):1.9662123
Number of Samples:13 / 5
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control normal skin tissue
Skin biopsy samples from healthy control subjects.

PMA study 2 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):1.7273045
Number of Samples:3 / 2
Experimental PMA study 2
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

cutaneous sarcoidosis study 1 (lesional) / cutaneous sarcoidosis study 1 (non-lesional)

Relative Expression (log2-ratio):1.7196474
Number of Samples:13 / 9
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control cutaneous sarcoidosis study 1 (non-lesional)
Non-lesional skin biopsies from patients with acute cutaneous sarcoidosis.

PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):1.639843
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

human AB serum study 1 (intermediate) / IL-4; GM-CSF study 1 (intermediate)

Relative Expression (log2-ratio):1.6036701
Number of Samples:3 / 7
Experimental human AB serum study 1 (intermediate)
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.

leprosy study 1 (LL) / leprosy study 1 (BTL)

Relative Expression (log2-ratio):1.571331
Number of Samples:6 / 10
Experimental leprosy study 1 (LL)
Lesional skin biopsy samples from patients with lepromatous leprosy (LL).
Control leprosy study 1 (BTL)
Lesional skin biopsy samples from patients with borderline tuberculoid leprosy (BTL)

male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-1.4915514
Number of Samples:2 / 8
Experimental male infertility study 1 (juvenile; Ad-)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

leprosy study 1 (RRL) / leprosy study 1 (LL)

Relative Expression (log2-ratio):-1.444624
Number of Samples:6 / 6
Experimental leprosy study 1 (RRL)
Lesional skin biopsy samples from patients with reversal reaction leprosy (RRL)
Control leprosy study 1 (LL)
Lesional skin biopsy samples from patients with lepromatous leprosy (LL).

PMA study 2 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):1.4357243
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.